| scholarly article | Q13442814 |
| P2093 | author name string | F Obermayr | |
| K J Tack | |||
| R Novak | |||
| G H Talbot | |||
| W T Prince | |||
| Z Ivezic-Schoenfeld | |||
| C Lell | |||
| P2860 | cites work | Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults | Q22242958 |
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| The pleuromutilin antibiotics: a new class for human use. | Q34095587 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections | Q35806254 | ||
| Staphylococcus aureus with reduced susceptibility to vancomycin | Q35882353 | ||
| Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. | Q36422630 | ||
| Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes | Q36486840 | ||
| Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection | Q38371341 | ||
| The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials | Q43795846 | ||
| Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms | Q46620675 | ||
| Managing skin and soft tissue infections: expert panel recommendations on key decision points | Q79353901 | ||
| Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs) | Q83353954 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2087-2094 | |
| P577 | publication date | 2013-02-19 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections | |
| P478 | volume | 57 |
| Q41872353 | A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism |
| Q30249262 | Antibiotics in the clinical pipeline at the end of 2015. |
| Q38133967 | Antibiotics in the clinical pipeline in 2013. |
| Q90131070 | Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents |
| Q38772340 | Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium |
| Q47780684 | Biosynthetic Machinery of Diterpene Pleuromutilin Isolated from Basidiomycete Fungi. |
| Q64268314 | Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis |
| Q64066325 | Current Treatment Options for Acute Skin and Skin-structure Infections |
| Q38239799 | Fungal natural products in research and development. |
| Q34525879 | In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States |
| Q52659745 | In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens. |
| Q40052692 | In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrhoeae |
| Q64072703 | In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model |
| Q64072714 | Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin |
| Q90284581 | Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270" |
| Q26796722 | Management of Mycoplasma genitalium infections - can we hit a moving target? |
| Q39362169 | Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon |
| Q42355223 | Mycoplasma genitalium infections: current treatment options and resistance issues |
| Q38247457 | Natural product and natural product derived drugs in clinical trials. |
| Q38172657 | New antibacterial agents: patent applications published in 2011. |
| Q38132217 | New antibiotics for bad bugs: where are we? |
| Q64072710 | Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing |
| Q37835585 | Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance |
| Q34508161 | Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. |
| Q34497915 | Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus |
| Q37570744 | The good, the bad and the tasty: The many roles of mushrooms |
Search more.